Compare Hims and Hers Health Inc (HIMS) vs SpaceX (SPCX) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

SPCX trades at $119.85, down 3.34% today and 45% below its post-IPO high, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 EPS of -$1.19, missing estimates by 260%, while revenue grew to $18.67B in 2025. SpaceX faces significant valuation concerns with a P/S of 84 and negative profitability metrics, though analyst consensus remains 100% buy-rated with a $237.78 price target representing 98% upside potential.

The stock presents high-risk/high-reward potential with strong institutional support but faces near-term headwinds from August lockup expirations and persistent losses. Long-term growth depends on Starlink expansion and AI contract wins, though current fundamentals don't justify the premium valuation. Investors must weigh analyst optimism against cash burn and execution risks in the competitive space sector.